For example, in the treatment of hematological malignancies, one of the main potential toxicities produced by CD22 as a CAR-T target is cytokine release syndrome (CRS) [24], and the drug tocilizumab (approved by FDA) is being extensively used to deal with CRS, which can block the activity of cytokines [25]. This evidence concerns the gene CD22 and hematologic disorder.